EUCTR2010-020772-38-IT进行中（未招募）不适用
A Phase II Study of Dose Density Regimen with Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days with Filgrastim Support followed by Weekly Paclitaxel in Women with Primary Breast Cancer. - ND
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients must have histologically or cytologically confirmed primary breast cancer •Age =18 and < 70 years •Eastern Cooperative Oncology Group (ECOG) performance status =1 •>4 positive axillary nodes or high-risk breast cancer with <4 node-positive or node negative disease. Patients <4 node-positive or node negative disease are eligible if the tumor is >1cm and two or more of the following are present: histologic grade 3, Ki67>30%, estrogen receptor (ER) negativity, or lymphovascular invasion [39] •Adequate hematological, hepatic and renal function, as follows: hemoglobin = 9 g/dl, absolute neutrophil count =1,500/?L, platelets =100,000/?L, total bilirubin =1.5 x ULN, alkaline phosphatase, AST(SGOT) and ALT(SGPT) = 2.5 x ULN (= 5 x ULN if liver metastases present), serum creatinine = 1.5 x ULN or calculated creatinine clearance >50 mL/min. Either INR or APTT < 1.5 x ULN; •Known hormone receptor status (ER/PgR or ER alone); •Must have received no other chemotherapy regimen. •Baseline LVEF =55% measured by echocardiography •No over expression and/or amplification of HER2 in the invasive component of the primary tumour (in case of neoadjuvant treatment, tissue sample used for HER2 testing should be collected before neoadjuvant treatment starts) •Negative pregnancy test no more than 7 days before randomization; test pregnancy can be omitted only in women without any reproductive potential (e.g.: postmenopausal women, i.e. amenorrhoea =2 years or with previous hysterectomy or bilateral ovariectomy). Women of child-bearing potential must agree to use adequate contraception at the time of randomization and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician and coordinating centre (CC) immediately; women in lactation period must be escluded; •Completion of all necessary baseline laboratory and radiological investigations •Ability to understand and the willingness to sign a written informed consent document. •Signed written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Metastatic disease •Participation in another clinical trial with any investigational agents within 30 days prior to study screening. •Contraindications or hypersensitivity to study drugs; •Past (less than 10 years) or current history of malignant neoplasms, except for curatively treated 1) basal and squamous cell carcinoma of the skin or 2) carcinoma in situ of the cervix. NOTE: Patients with a prior malignancy diagnosed greater than 10 years in the past who have been curatively treated with surgery ONLY, WITHOUT radiation therapy or systemic therapy (chemotherapy or endocrine) are eligible for the study. Patients with any prior diagnosis of invasive breast cancer or melanoma, at any time, are excluded from this study. •Serious cardiac illness or medical conditions including but not confined to: History of documented congestive heart failure (CHF) or systolic dysfunction (LVEF <55%); – High-risk uncontrolled arrhythmias (ventricular tachycardia, high-grade AV-block, supraventricular arrhythmias which are not adequately rate-controlled); – Angina pectoris requiring antianginal medication; – Clinically significant valvular heart disease; – Evidence of transmural infarction on ECG; – Poorly controlled hypertension (e.g. systolic >180mm Hg or diastolic >100mm Hg); •Other concurrent serious diseases that may interfere with planned treatment including severe pulmonary conditions/illness; •Malabsorption syndrome, any disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, or persons unable to swallow oral medication. Subjects with ulcerative colitis are also excluded; • Pregnant, lactating or women of childbearing potential without a negative pregnancy test – urine or serum, within 7 days prior to randomization, irrespective of the method of contraception used, including tubal ligation. • Women of childbearing potential, including women whose last menstrual period was <12 months ago (unless surgically sterile) who are unable or unwilling to use adequate contraceptive measures during study treatment. (adequate contraceptive measures are intra-uterine device, barrier method - condoms, diaphragm - also in conjunction with spermicidal jelly, or total abstinence. Oral, injectable or implant hormonal contraceptives are not allowed on this study)
研究者
相似试验
进行中（未招募）
不适用
Randomized Phase II Study of Dose-Dense Fluorouracil Plus Epirubicin75 Plus Cyclophosphamide (FEC75) and Fluorouracil Plus Epirubicin90 Plus Cyclophosphamide (FEC90) as Adjuvant Therapy for Early Breast Cancer - not availableEarly Breast CancerMedDRA version: 7.0Level: PTClassification code 10006199EUCTR2004-000806-39-HUCECOG50
进行中（未招募）
1 期
Randomized Phase II Study of Dose-Dense Fluorouracil Plus Epirubicin75 Plus Cyclophosphamide (FEC75) and Fluorouracil Plus Epirubicin90 Plus Cyclophosphamide (FEC90) as Adjuvant Therapy for Early Breast CancerEarly Breast CancerMedDRA version: 7.0Level: PTClassification code 10006199EUCTR2004-000806-39-SKCECOG50
已完成
不适用
A PHASE I/II DOSE-FINDING STUDY OF HIGH-DOSE FLUCONAZOLE TREATMENT IN AIDS-ASSOCIATED CRYPTOCOCCAL MENINGITIS-B24 Unspecified human immunodeficiency virus [HIV] diseaseUnspecified human immunodeficiency virus [HIV] diseaseB24PER-030-10INSTITUTO NACIONAL DE ALERGIAS Y ENFERMEDADES INFECCIOSAS DE LOS ESTADOS UNIDOS, SOCIAL & SCIENTIFIC SYSTEMS, INC,,
招募中
1 期
High-Dose Fluconazole for the Treatment of CM in HIV-infected PeopleCTRI/2013/04/003545Division of AIDS DAIDS NIH USA Division of AIDS DAIDS NIH USA192
进行中（未招募）
不适用
A Dose Targeted Phase I/II Study To Evaluate The Feasibility, Safety, And Biological Effects Of Intravenous Administration of A Wild-Type Reovirus (REOLYSIN®) in Combination With Paclitaxel and Carboplatin To Patients With Advanced MalignanciesAdvanced or metastatic solid tumours that are refractory to standard therapy or for which no curative standard therapy exists and for which paclitaxel plus carboplatin is appropriate palliative chemotherapy.MedDRA version: 8.1Level: LLTClassification code 10049280Term: Solid tumourEUCTR2006-006515-76-GBOncolytics Biotech Inc